Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $77.10.
Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. UBS Group reduced their target price on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Robert W. Baird reduced their target price on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Baird R W raised shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a report on Monday, July 22nd. Finally, Barrington Research reduced their target price on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th.
Read Our Latest Stock Report on Henry Schein
Henry Schein Stock Down 1.2 %
Henry Schein (NASDAQ:HSIC – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.01. The company had revenue of $3.10 billion for the quarter, compared to analyst estimates of $3.27 billion. Henry Schein had a net margin of 3.12% and a return on equity of 13.51%. Henry Schein’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.31 EPS. Sell-side analysts anticipate that Henry Schein will post 5.16 earnings per share for the current year.
Institutional Trading of Henry Schein
A number of institutional investors have recently bought and sold shares of HSIC. Swedbank AB bought a new stake in Henry Schein in the 1st quarter valued at about $215,998,000. Boston Partners raised its position in shares of Henry Schein by 144.1% in the 4th quarter. Boston Partners now owns 2,637,429 shares of the company’s stock valued at $199,393,000 after buying an additional 1,556,831 shares in the last quarter. Norges Bank acquired a new position in shares of Henry Schein in the 4th quarter valued at approximately $111,715,000. Nuance Investments LLC acquired a new position in shares of Henry Schein in the 4th quarter valued at approximately $103,446,000. Finally, Thompson Siegel & Walmsley LLC acquired a new position in shares of Henry Schein in the 2nd quarter valued at approximately $46,683,000. Institutional investors own 96.62% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Articles
- Five stocks we like better than Henry Schein
- Stock Average Calculator
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Stock Analyst Ratings and Canadian Analyst Ratings
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Investing In Preferred Stock vs. Common Stock
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.